Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
October 24, 2023
Assignee:
Neurelis, Inc.
Inventors:
Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.
Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Application
Filed:
December 6, 2022
Publication date:
April 6, 2023
Applicant:
Neurelis, Inc.
Inventors:
Steve CARTT, David MEDEIROS, Garry Thomas GWOZDZ, Andrew LOXLEY, Mark MITCHNICK, David F. HALE, Edward T. MAGGIO
Abstract: Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.
Type:
Application
Filed:
June 10, 2022
Publication date:
December 22, 2022
Applicant:
Neurelis, Inc.
Inventors:
Adrian L. Rabinowicz, Enrique J. Carrazana
Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Application
Filed:
April 15, 2022
Publication date:
August 4, 2022
Applicant:
Neurelis, Inc.
Inventors:
Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
Abstract: Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.
Type:
Application
Filed:
January 7, 2022
Publication date:
July 14, 2022
Applicant:
Neurelis, Inc.
Inventors:
Sunita Misra, Enrique J. Carrazana, Adrian L. Rabinowicz, Stuart Madden, Edward T. Maggio
Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Application
Filed:
June 2, 2021
Publication date:
April 21, 2022
Applicant:
Neurelis, Inc.
Inventors:
Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
February 8, 2022
Assignee:
Neurelis, Inc.
Inventors:
Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Type:
Application
Filed:
May 27, 2021
Publication date:
September 30, 2021
Applicant:
Neurelis, Inc.
Inventors:
Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio